Company Profile

LYSOGENE is a biotechnology company specializing in the research and development of gene therapies for the treatment of rare neurodegenerative diseases. The company now has 2 drug candidates in clinical development of which 1 in phase 2/3 (LYS-SAF302 for the treatment of Sanfilippo syndrome type A) and 1 in phase 1/2 (LYS-GM101 for the treatment of GM1 gangliosidosis).

Employees

Sector

Biotechnology & Medical Research

More about the company

06/07/23	Lysogene S.A.(ENXTPA:LYS) dropped from CAC AllShares Index	CI
06/07/23	Lysogene S.A.(ENXTPA:LYS) dropped from Next Biotech Index	CI
14/06/23	Lysogene CFO Assumes Same Role at Mauna Kea Technologies	MT
29/05/23	Lysogene: placed in liquidation and delisted
29/05/23	Lysogene to Delist from Euronext amid Judicial Liquidation	MT
29/04/23	Lysogene S.A. Announces Postponement of 2022 Financial Results Release	CI
17/04/23	Lysogene: no takeover bid received for biotech company
17/04/23	Lysogene Fails to Secure Takeover Bid Amid Reorganization	MT
27/03/23	Lysogene: deadline for takeover bids extended
06/02/23	Lysogene: interim CFO confirmed
06/02/23	French Gene Therapy Group Lysogene Makes Ad Interim CFO Permanent	MT
03/02/23	Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer	CI
25/01/23	Lysogene: company placed in receivership

10/10/23	Fragile X Syndrome Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	AQ
18/09/23	Fragile X Syndrome Pipeline, Clinical Trials and NDA Approvals 2023 (Updated)	AQ
29/04/23	LYSOGENE : Inside Information / News release on accounts, results	PU
06/12/22	LYSOGENE : Inside Information / Operations of the issuer (acquisitions, sales...)	PU
30/11/22	Lysogene : Announces Favorable DSMB Review Recommending Study Continuation and Positive Biomarker Data in Stage 1 of Adaptative Clinical Trial with LYS-GM101 Gene Therapy in GM1 Gangliosidosis	PU

14/06/23	Mauna Kea Technologies : A suivre aujourd'hui
13/06/23	Mauna Kea Technologies : Côme de La Tour du Pin (ex-Lysogene) nommé Directeur financier
29/05/23	Lysogene : placé en liquidation et retiré de la cote
16/05/23	Lysogène: audience le 23 mai sur une possible liquidation judiciaire
02/05/23	Lysogene : reporte la publication de ses résultats et envisage une liquidation judiciaire

Manager	Title	Age	Since
Karen Pignet-Aiach CEO	Chief Executive Officer	54	08/05/2014
Côme de La Tour du Pin DFI	Director of Finance/CFO	-	31/10/2022
Marie Trad CTO	Chief Tech/Sci/R&D Officer	-	31/01/2022

Director	Title	Age	Since
Karen Pignet-Aiach CHM	Chairman	54	21/05/2019
Peter Lichtlen BRD	Director/Board Member	58	31/03/2018
Carole Deffez BRD	Director/Board Member	-	25/09/2019

LYSOGENE Share Price

Stocks

LYS

FR0013233475

Biotechnology & Medical Research

Latest news: LYSOGENE

Press Releases: LYSOGENE

News in other languages: LYSOGENE

Managers and Directors: LYSOGENE

Bio Diagnostics & Testing

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LYSOGENE	-.--%	-.--%	-	-	5.53M
WUXI APPTEC CO., LTD.	-0.21%	-6.36%	+49.00%	+74.13%	66.34B
LONZA GROUP AG	-0.22%	+10.10%	+12.77%	+87.32%	52.92B
ARGENX SE	+0.82%	+9.46%	+7.75%	+73.53%	54.82B
IQVIA HOLDINGS INC.	+3.28%	+6.12%	+30.46%	+50.05%	44.09B
BEONE MEDICINES AG	+0.51%	+10.71%	+21.30%	+133.92%	43.72B
REVOLUTION MEDICINES, INC.	-1.15%	+3.10%	+259.71%	+594.60%	42.13B
CELLTRION, INC.	+0.10%	+9.96%	+17.15%	+59.33%	33.96B
WUXI BIOLOGICS (CAYMAN) INC.	-1.30%	-3.61%	+37.37%	+7.16%	26.17B
GENMAB A/S	+0.69%	+6.07%	+31.89%	+26.94%	23.37B
Average	+0.25%	+4.78%	+51.93%	+123.00%	43.06B
Weighted average by Cap.	+0.32%	+4.67%	+51.28%	+127.77%